Efficacy after Transition to SB5 from Reference Adalimumab (Humira (R)) Vs. Continuation of SB5 or Reference Adalimumab By Antibodies Developed after Transition from a SB5 Phase III Study Genovese, M. C., Weinblatt, M., Keystone, E. C., Baranauskaite, A., Cheong, S., Ghil, J. WILEY. 2016

View details for Web of Science ID 000417143401028